3M Expands its Medical Diagnostics Platform with Acquisition of Acolyte Biomedica Ltd.

19-Feb-2007

3M announced it has acquired Acolyte Biomedica Ltd. Acolyte Biomedica brings to 3M's infection prevention platform a pipeline of rapid culture-based screening tests for microbes, such as MRSA and vancomycin-resistant enterococcus (VRE), that simplify the diagnostic process by automating traditional culture methodology resulting in reliable confirmed 'negatives' in hours rather than days.

According to the compnay, the addition of Acolyte Biomedica allows 3M to expand more quickly into the emerging market of infection prevention diagnostics, especially in Europe where Acolyte Biomedica has commercialized product for MRSA.

Other news from the department business & finance

Most read news

More news from our other portals

See the theme worlds for related content